ClinicalTrials.gg
CompletedNCT00002345Updated Oct 2, 2007

The Safety and Effectiveness of Megace in HIV-Infected Women

A Phase 4 interventional study of Megestrol acetate in Anorexia, Cachexia and HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-10-02.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Megestrol Acetate in Anorexia — 1 open to participants now, 1 under way, none of them phase 3. Megestrol Acetate · Anorexia.

Enrollment
4th of 10
40 · median 19
Phase 4
Only one
of the 12
Registered
1st of 12
by date
Lead sponsor
3 of 12
Bristol-Myers Squibb

Among the 12 studies testing Megestrol Acetate in Anorexia, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one in phase 4, and was the 1st registered.

Anorexia

163 studies on the registry are indexed under Anorexia; 25 are open to participants now.

Browse Anorexia studies →

Open to participants now

1 of the 12 studies testing Megestrol Acetate in Anorexia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Megestrol Acetate

Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Anorexia studies recruiting now, 6 (50%) set no upper age limit and 6 (50%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Megestrol Acetate in Anorexia, or all of them as a file.
02

Study summary

To further evaluate the safety of megestrol acetate (Megace) oral suspension in the treatment of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2 doses of Megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24 weeks.

Read the detailed description

Patients are randomized to receive 1 of 2 doses of Megace oral suspension daily for 24 weeks; at 12 weeks, those receiving the lower dose who have not gained 5 pounds over baseline or had appetite improvement to good or excellent are escalated to the higher dose. Patients are evaluated at 4-week intervals. Dose may be adjusted to maintain a desired weight.

03

Conditions studied

  • Anorexia
  • Cachexia
  • HIV Infections

Keywords

  • Megestrol
  • Acquired Immunodeficiency Syndrome
  • Anorexia
  • Cachexia
  • Suspensions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient must have:

  • infection.
  • Evidence of HIV wasting syndrome that includes anorexia (appetite fair or poor) and weight loss >= 10 percent of pre-illness body weight.
  • Perception of weight loss as a detriment.
  • of at least 24 weeks.

Prior Medication:

Allowed:

  • Megestrol acetate for weight gain at a dose \< 400 mg for \< 60 days, provided therapy was discontinued at least 3 months prior to study entry.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Poorly controlled hypertension.
  • Heart failure.
  • Deep vein thrombosis.
  • Uncontrolled severe diarrhea.
  • Treatable active current infection (excluding chronic low-grade opportunistic infections).
  • Unable to intake food.
  • Impaired digestive/absorptive function.

Concurrent Medication:

Excluded:

  • Initiation during the study of any therapy to treat or anorexia/cachexia (other than study drug).

Patients with the following prior conditions are excluded:

  • Hospitalization for or exacerbation of illness associated with weight loss within the past 2 weeks.
  • Participation in other drug studies within the past month.
  • Previous abnormal mammogram (if 35-40 years of age) or abnormal mammogram within the past year (if over 40 years of age).

Prior Medication:

Excluded:

  • New antiviral therapy within the past 8 weeks.
  • Medications to promote weight gain (e.g., , dronabinol) within the past 2 months.
  • Megestrol acetate within the past 3 months. IV drug abuse not treated for at least 4 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Enrollment
40 participants

Interventions

06

Study locations

4 sites
  • Univ of California - Davis Med Ctr / CARES
    Sacramento, California 95817, United States
  • Yale Univ Med School
    New Haven, Connecticut 065102483, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 200072197, United States
  • Miriam Hosp
    Providence, Rhode Island 02906, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002345
First posted
Aug 31, 2001
Last update
Oct 2, 2007
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion